Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials(1). One PARP inhibitor, olaparib (Lynparza(™), AstraZeneca), was recently approved by the FDA to treat ovarian cancer with BRCA mutations. BRCA1 and BRCA2 pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yi, Yamaguchi, Hirohito, Wei, Yongkun, Hsu, Jennifer L., Wang, Hung-Ling, Hsu, Yi-Hsin, Lin, Wan-Chi, Yu, Wen-Hsuan, Leonard, Paul G., Lee, Gilbert R., Chen, Mei-Kuang, Nakai, Katsuya, Hsu, Ming-Chuan, Chen, Chun-Te, Sun, Ye, Wu, Yun, Chang, Wei-Chao, Huang, Wen-Chien, Liu, Chien-Liang, Chang, Yuan-Ching, Chen, Chung-Hsuan, Park, Morag, Jones, Philip, Hortobagyi, Gabriel N., Hung, Mien-Chie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754671/
https://www.ncbi.nlm.nih.gov/pubmed/26779812
http://dx.doi.org/10.1038/nm.4032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754671/
https://www.ncbi.nlm.nih.gov/pubmed/26779812
http://dx.doi.org/10.1038/nm.4032

Ejemplares similares